Search CTL/CD8+ T-Cell Epitope Database

Found 2 matching records:

Displaying record number 56146

Download this epitope record as JSON.

HXB2 Location	Vif(32-40) DNA(5134..5160)	Vif Epitope Map
Author Location	Vif
Epitope	SKRASGWFY	Epitope Alignment
		Show epitope variants
Subtype	C
Species (MHC/HLA)	human(B*15:03)
Immunogen	HIV-1 infection
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	HLA associated polymorphism

Notes

• 3 phylogenetic correction methods---MLL (maximum likelihood character state analysis followed by likelihood ratio test), MLF (maximum likelihood character state analysis followed by Fisher test), and parsimony character state analysis were used to identify points in the HIV-1 subtype C proteome that conferred susceptibility or resistance to CTLs. Associations of HLA-epitope combinations that were inferred to be susceptible or resistant were organized into immunological sets that would help identify the best residues and genes as candidates for vaccines. While all proteins were interrogated, Gag, Pol, Env and Nef were focused upon. Amino acid changes were evaluated for association with plasma viral load.
• Proteome maps may be seen at http://www.hiv.lanl.gov/content/immunology/hlatem/study5/index.html with information showing single or multiple sites involving escape and reversion.
• HLA- B and -C alleles associated more with aa changes than HLA-A, suggesting that the former two are more important in driving viral evolution.
• The ratio of susceptible to resistant residues in HIV proteins was in descending order, Vpr>Gag>Rev>Pol>Nef>Vif>Tat>Env>Vpu, showing that epitopes from the earlier proteins are more conserved owing to viral fitness cost upon mutation.
• This previously described Vif HLA B*1503-restricted epitope, SKRASGWFY was susceptible at K2. Variants SgRASGWFY, SqRASGWFY and SrRASGWFY were resistant to CTL response, but associated with lower viral loads. This epitope is 1 of 7 that suggest a fitness cost to immune escape.

References

Rousseau2008 Christine M. Rousseau, Marcus G. Daniels, Jonathan M. Carlson, Carl Kadie, Hayley Crawford, Andrew Prendergast, Philippa Matthews, Rebecca Payne, Morgane Rolland, Dana N. Raugi, Brandon S. Maust, Gerald H. Learn, David C. Nickle, Hoosen Coovadia, Thumbi Ndung'u, Nicole Frahm, Christian Brander, Bruce D. Walker, Philip J. R. Goulder, Tanmoy Bhattacharya, David E. Heckerman, Bette T. Korber, and James I. Mullins. HLA Class I-Driven Evolution of Human Immunodeficiency Virus Type 1 Subtype C Proteome: Immune Escape and Viral Load. J. Virol., 82(13):6434-6446, Jul 2008. PubMed ID: 18434400. Show all entries for this paper.

Displaying record number 61464

Download this epitope record as JSON.

HXB2 Location	Vif(32-40) DNA(5134..5160)	Vif Epitope Map
Author Location	Vif(32-40)
Epitope	SKRASGWFY	Epitope Alignment
		Show epitope variants
Subtype	C
Species (MHC/HLA)	human(B*15:03)
Immunogen	HIV-1 infection
Patient MHC/HLA	E_3430: A*29:02, A*74:01, B*13:02, B*15:03, C*02:10, C*06:02
Country	Botswana
Experimental methods	Other
Keywords	dynamics, acute/early infection, chronic infection

Notes

• HIV-1C epitope variants in accessory proteins Vif, Vpr but not Vpu found during early infection show constrained diversity when compared to variants during chronic infection. T/F (transmitted founder) variants were examined over 500 days post-seroconversion (p/s) in 17 infected patients, either in acute or early infection, and were compared to an independent data set of chronic sequence changes.
• Patient E_3430 was seen to carry different variants of Vif published (Rousseau et al.) epitope SKRASGWFY over 372 days p/s - SKkAkGWFY, SKktkGWFY and SektkGWsY.

References

Rossenkhan2016 Raabya Rossenkhan, Iain J. MacLeod, Zabrina L. Brumme, Craig A. Magaret, Theresa K. Sebunya, Rosemary Musonda, Berhanu A. Gashe, Paul T. Edlefsen, Vlad Novitsky, and M. Essex. Transmitted/Founder HIV-1 Subtype C Viruses Show Distinctive Signature Patterns in Vif, Vpr, and Vpu That Are Under Subsequent Immune Pressure During Early Infection. AIDS Res. Hum. Retroviruses, 32(10-11):1031-1045, Oct/Nov 2016. PubMed ID: 27349335. Show all entries for this paper.